SHPG - Shire plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
144.99
-0.70 (-0.48%)
As of 3:19PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close145.69
Open145.90
Bid144.58 x 400
Ask144.70 x 100
Day's Range143.54 - 146.05
52 Week Range137.17 - 192.15
Volume819,556
Avg. Volume1,202,208
Market Cap41.978B
Beta1.89
PE Ratio (TTM)27.40
EPS (TTM)5.29
Earnings DateN/A
Forward Dividend & Yield0.92 (0.63%)
Ex-Dividend Date2017-09-07
1y Target Est213.93
Trade prices are not sourced from all markets
  • GlobeNewswire10 hours ago

    Shire plc : Directorate change

    Directorate Change Dublin, Ireland - January 19, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces that Thomas Dittrich will assume his role as Chief Financial Officer, and ...

  • How Is Bioverativ’s Alprolix Positioned Now?
    Market Realist8 days ago

    How Is Bioverativ’s Alprolix Positioned Now?

    In 3Q17, Bioverativ’s (BIVV) drug Alprolix generated revenue of $88.5 million, which reflected a rise of ~4% on a year-over-year (or YoY) basis. In 3Q17, Alprolix contributed ~32.2% of Bioverativ’s net product sales. Alprolix reported revenue of $264.2 million in the first nine months of 2017 (which ended in September 2017) compared to its revenue of $240.5 million in the first nine months of 2016.

  • How Is Roche’s Hemlibra Positioned for 2018?
    Market Realist8 days ago

    How Is Roche’s Hemlibra Positioned for 2018?

    What to Expect from Roche in 2018

  • Reuters11 days ago

    Shire cuts 2020 revenue target, prepares for spin-off of ADHD drugs

    Shire (SHP.L) ditched its revenue target of $20 billion (14.8 billion pounds) by 2020 on Monday due to increased generic competition and new drugs from rivals, saying it would split its rare disease and hyperactivity medicines businesses to boost performance. The London-listed pharmaceutical group said total revenue would now reach $17-18 billion by 2020, dropping the goal set two years ago when it acquired haemophilia specialist Baxalta. Chief Executive Flemming Ornskov, said that revenue had tripled to $15 billion in five years and that $20 billion was a "stretch target".

  • American City Business Journals11 days ago

    Shire cuts sales outlook; still considering spinout of ADHD drugs

    Rare disease drugmaker Shire cut its 2020 revenue forecast on Monday, and announced that it plans to split its ADHD drugs into a separate division, with a possible spinout in the future. Shire (SHPG), the state’s second largest biopharma employer, said that it is now projecting its total revenue to reach $17 billion to $18 billion by 2020. Shares of Shire were down more than 4 percent as of 11 a.m., shaving nearly $2 billion off its market capitalization, which was around $45 billion before the selloff.

  • Reuters11 days ago

    Shire to separate ADHD drugs before possible spin-off, cuts 2020 target

    London-listed pharmaceutical group Shire said on Monday it would create two distinct business units for its rare disease and hyperactivity medicines before deciding later this year whether to spin off the latter into a separately listed group. Shire said that following a review it had decided its neuroscience business, which makes the attention deficit hyperactivity disorder (ADHD) blockbuster Vyvanse, warranted additional focus and investment. "Shire has undergone a significant transformation over the last five years creating two market-leading businesses with distinct profiles and future needs," chief executive Flemming Ornskov said.

  • GlobeNewswire11 days ago

    Shire Announces Business Update at 36th Annual J.P. Morgan Healthcare Conference

                Shire Announces Business Update at 36 th Annual J.P. Morgan Healthcare Conference Projects continued strong growth as the global leader in rare diseases, led by the immunology franchise Will ...

  • Market Realist14 days ago

    How Novo Nordisk’s Biopharmaceuticals Segment Performed in 3Q17

    In 3Q17, Novo Nordisk’s (NVO) hemophilia segment reported revenues of 2.4 billion Danish krone (or DKK), a ~10% increase on a YoY basis.

  • Reuters14 days ago

    Future of Kala Pharma's dry eye drug uncertain after mixed results

    Mixed results from two late-stage studies testing Kala Pharmaceuticals Inc's drug to provide temporary relief from dry eye disease cast doubt on the drug's path forward and sent shares down 16 percent in early trading on Friday. "The question is will the FDA accept this or make them do another trial before approval?" Wedbush analyst Liana Moussatos told Reuters, dubbing Kala's first trial "the best results" for dry eye she'd seen in a late-stage study.

  • GlobeNewswire15 days ago

    Shire to present at the 36th Annual J.P. Morgan Healthcare Conference

    Shire to present at the 36th Annual J.P. Morgan Healthcare Conference Cambridge, MA - January 4, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) announces that Flemming Ornskov, M.D., M.P.H., Chief Executive ...

  • GlobeNewswire17 days ago

    Shire plc : Total voting rights

    Total Voting Rights January 2, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company"), in accordance with 5.6.1R of the Financial Conduct Authority`s (the "FCA") Disclosure Guidance ...

  • GlobeNewswire17 days ago

    Shire plc : Director Declaration

    Director Declaration Dublin, Ireland - January 2, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces that Dominic Blakemore, Non-Executive Director of the Company, was appointed ...

  • Shire Plc :SHPG-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018
    Capital Cube18 days ago

    Shire Plc :SHPG-US: Earnings Analysis: Q3, 2017 By the Numbers : January 1, 2018

    Categories: Yahoo FinanceGet free summary analysis Shire Plc reports financial results for the quarter ended September 30, 2017. Highlights Summary numbers: Revenues of USD 3,720.03 million, Net Earnings of USD 554.54 million. Gross margins widened from 38.31% to 58.52% compared to the same period last year, operating (EBITDA) margins now 42.01% from 12.23%. Change in operating cash ... Read more (Read more...)

  • Protalix (PLX) Fabry Disease Candidate Gets Orphan Status
    Zacks22 days ago

    Protalix (PLX) Fabry Disease Candidate Gets Orphan Status

    Protalix BioTherapeutics's (PLX) pipeline candidate, PRX-102, gets orphan drug status in Europe which is being developed as a treatment for Fabry disease.

  • Morningstar22 days ago

    Healthcare: Pick Carefully as Valuations Head Higher

    Innovation and redeployment of capital are factoring heavily in the sector.

  • Barrons.com23 days ago

    Shire: If You Build It…

    Shares of Shire (SHPG) are lower on Wednesday, after the drug maker said it filed its first submission for its new plasma manufacturing facility in Georgia to the Food and Drug Administration. Cantor Fitzgerald's Louise Chen and her team write that the new facility will support Shire's immunology franchise, which has seen sales climb some 21% in 2017, easily above the 6% to 8% growth the company originally expected. SHPG guided to overall gross margins of 74.5%-76.5% in 2017 for the entire business, but did not break this out by business segments.

  • Capital Cube23 days ago

    ETFs with exposure to Shire Plc : December 27, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Shire Plc Here are 5 ETFs with the largest exposure to SHPG-US. Comparing the performance and risk of Shire Plc with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • GlobeNewswire23 days ago

    Shire files for FDA approval of a new plasma manufacturing facility in Covington, Georgia to support growing Immunology franchise

    Shire files for FDA approval of a new plasma manufacturing facility in Covington, Georgia to support growing Immunology franchise Dublin, Ireland - December 27, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG), ...

  • Will Shire plc’s (LON:SHP) Earnings Grow Over The Next Few Years?
    Simply Wall St.25 days ago

    Will Shire plc’s (LON:SHP) Earnings Grow Over The Next Few Years?

    The most recent earnings update Shire plc’s (LSE:SHP) released in September 2017 indicated that the business experienced a major headwind with earnings deteriorating by -54.88%. Below, I’ve presented key growthRead More...

  • Morningstar28 days ago

    Rare-Disease Portfolio Digs Shire a Moat

    We think many of its drugs are relatively more resistant to patent cliffs or sales pressure from generics.

  • Shire plc (NASDAQ:SHPG): What Can We Expect From This High Growth Stock?
    Simply Wall St.29 days ago

    Shire plc (NASDAQ:SHPG): What Can We Expect From This High Growth Stock?

    Shire plc’s (NASDAQ:SHPG) most recent earnings announcement in September 2017 revealed that the business endured a immense headwind with earnings falling by -54.88%. Below, I’ve presented key growth figures onRead More...

  • GlobeNewswirelast month

    Shire plc : Director/PDMR Shareholding

    Director/PDMR Shareholding   December 20, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG)   Notification of transactions by persons discharging managerial responsibilities   1. Details of the person discharging ...

  • Reuterslast month

    Shire's Hunter syndrome drug fails late-stage study

    Shire Plc's experimental treatment for children with Hunter syndrome and cognitive impairment failed to meet the main and secondary goals of a late-stage clinical trial. The trial evaluated the efficacy of Shire's treatment, SHP609, based on changes in cognition between children treated with the drug and those on a placebo, the London-listed drugmaker said on Tuesday. Hunter syndrome is a rare, inherited metabolic disorder that mainly affects males.

  • MarketWatchlast month

    Shire's stock falls after drug trial misses primary and secondary endpoints

    The U.S.-listed shares of Shire PLC fell 1.2% in premarket trade Tuesday, after the Ireland-based drug maker said a phase 2/3 trial of its treatment for Hunter syndrome in pediatric patients failed to ...

  • Reuterslast month

    Shire says Hunter syndrome treatment fails in key study

    Shire Plc's investigational drug for treating pediatric patients with Hunter syndrome and cognitive impairment failed to meet the main goal of a late-stage trial. The clinical trial evaluating SHP609, ...